The effectiveness of malaria camps as part of the Durgama Anchalare Malaria Nirakaran (DAMaN) program in Odisha, India: study protocol for a cluster-assigned quasi-experimental study

Danielle C. Ompad, Anne Kessler, Anna Maria Van Eijk, Timir K. Padhan, Mohammed A. Haque, Steven A. Sullivan, Yeşim Tozan, Joacidm Rocklović, Catriona L.E.B. Patterson, Kevin K.A. Tetteh, Sanjib Mohanty, Madan M. Pradhan, Praveen K. Sahu, and Jane M. Carlton

School of Global Public Health, New York University, New York, NY, USA; Center for Genomics and Systems Biology, Department of Biology, New York University, New York, NY, USA; Department of Molecular & Infectious Diseases, Community Welfare Society Hospital, Rourkela, Odisha, India; Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, England, WC1E 7HT, UK; Department of Health & Family Welfare, State Vector Borne Disease Control Programme, Bhubaneswar, Odisha, India

ABSTRACT

The Indian state of Odisha has a longstanding battle with forest malaria. Many remote and rural villages have poor access to health care, a problem that is exacerbated during the rainy season when malaria transmission is at its peak. Approximately 62% of the rural population consists of tribal groups who are among the communities most negatively impacted by malaria. To address the persistently high rates of malaria in these remote regions, the Odisha State Malaria Control Program introduced ‘malaria camps’ in 2017 where teams of health workers visit villages to educate the population, enhance vector control methods, and perform village-wide screening and treatment. Malaria rates declined statewide, particularly in forested areas, following the introduction of the malaria camps, but the impact of the intervention is yet to be externally evaluated. This study protocol describes a cluster-assigned quasi-experimental stepped-wedge study with a pretest-posttest control group design that evaluates if malaria camps reduce the prevalence of malaria, compared to control villages which receive the usual malaria control interventions (e.g. IRS, ITNs), as detected by PCR.

Background

Despite declines over the past decade, malaria remains an important global public health problem in India. India is one of twenty countries accounting for 85% of all malaria cases and deaths in 2018 and 47% of all Plasmodium vivax cases globally [1]. Of note, between 2017 and 2018 there was a 27% reduction in reported malaria cases, a margin of 2.6 million cases [1]. The eastern Indian state of Odisha accounted for 40.9% of cases in 2016, 41.2% in 2017, 15.4% in 2018, 11.8% in 2019, and 27.8% in 2020 (through February) [2], despite comprising only 4.9% of the nation’s land area [3] and 3.5% of its population [4].

Odisha is known for its hilly, forested, and inaccessible regions, and for the indigenous ‘tribal’ people who live there. (Although the global term ‘indigenous peoples’ is widely used in the literature, it is a debated term in India [5]. The Indian government uses the term ‘tribal’ or the constitutionally-recognized category of ‘Scheduled Tribes’ to refer to these communities [6].) Tribal communities in India are particularly prone to malaria due to geographical marginalization, poor access to health care, low socioeconomic status, and other social factors including cultural and religious values and beliefs [7,8]. Odisha is divided into 30 districts [9], 314 blocks, and 53,845 villages [10]. The climate is subtropical, with four seasons: winter (January–February), pre-monsoon (March–May), southwest monsoon (June–September), and northeast monsoon (October–December) [3]. More than 47,000 Accredited Social Health Activists (ASHAs; community health workers) are involved in malaria control activities [11,12].

Malaria transmission occurs predominantly in forested and forest fringe regions in Odisha, with many communities experiencing poor access to health care, especially during the rainy season. Plasmodium falciparum is the major parasite species (>90% of cases), and the major malaria vectors are Anopheles fluviatilis found in inaccessible, hilly, and forested regions [13,14], and Anopheles culicifacies spp. C and E in plains villages where they breed in rice fields [15,16]. Even on a relatively small spatial scale (e.g. a village), malaria transmission is heterogeneous, with a subset of people experiencing greater rates of mosquito biting [17].

CONTACT Danielle C. Ompad dco2@nyu.edu NYU School of Global Public Health, 715 Broadway, Room 1011, New York, NY 10003 USA PKS and JMC are joint last authors.
Trial registration: Clinical Trials.gov #: NCT03953689, registered September 2019
This article was originally published with errors, which have now been corrected in the online version. Please see Correction (10.1080/16549716.2022.207685)
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Distribution of insecticide-treated nets (ITNs) in areas with an annual parasite incidence (API; cases per 1,000 people) ≥2 forms an important part of malaria control in the state, and indoor residual spraying (IRS) with dichlorodiphenyltrichloroethane (DDT) is offered twice a year in high-risk malarious areas. In 2016, 58.3% of blocks had an API ≥2, with 34.4% ≥10.

Antimalarial drug resistance has been reported in *P. falciparum* infections at various sites in Odisha, primarily through molecular studies that sequence the parasite genes known to be involved. For example, mutations in *P. falciparum* genes associated with chloroquine resistance [18–21] and sulphadoxine-pyrimethamine resistance [19,20] have been identified throughout the state. Routine molecular surveillance of parasites in these areas has also identified changes in the frequency of drug resistant mutations as different antimalarial drugs have been discontinued, such as the reversion to sensitive genotypes due to removal of the drug chloroquine [19]. More recently, sequencing studies have been used to identify if mutations in the *P. falciparum* kelch13 gene, implicated in resistance to artemisinin, have arisen in multiple parts of Odisha [19,22], but as yet no such mutations have been identified.

The persistently high malaria burden in remote forested areas of Odisha has led to the introduction of ‘malaria camps’ (MCs) by the Odisha State Malaria Control Program (MCP), where teams of health workers visit villages to educate the population, enhance vector control with long-lasting insecticide-treated nets (LLINs) and IRS, and perform village-wide screening with rapid diagnostic tests (RDTs) and treatment for malaria. The MCs are part of a program, Durgama Anchalare Malaria Nirakaran (DAMAN) ‘malaria control in inaccessible areas,’ and have two main components, mass screening and treatment of all malaria positive cases and simultaneous intensive vector control using LLIN and IRS, allowing for both the parasite and mosquito to be targeted in parallel. The camps appear to be effective, but this has been hard to assess in the context of ongoing changes such as LLIN introduction. The goal of the study protocol described here is to evaluate the effectiveness of MCs on malaria prevalence.

**Methods/design**

**Aims and objectives**

The goal of this protocol is to evaluate the effectiveness of malaria camps (MCs) by determining if they reduce malaria and to characterize malaria transmission in intervention villages over time. Specifically, this pilot study is designed to demonstrate proof-of-concept and feasibility, and aims to assess if MCs in intervention villages reduce the prevalence of malaria compared to standard malaria control efforts in control villages. In addition, the study aims to investigate the out-of-pocket costs and impact of malaria from the patient’s perspective in these hard-to-reach tribal communities.

Secondary objectives of this study include: determining if MCs reduce the prevalence of subpatent, symptomatic, and asymptomatic malaria as detected in the study surveys as well as in local clinics (e.g. passive case data collected through existing surveillance networks; symptomatic malaria prevalence only); assessing malaria exposure, immunity, and risk among participants in each arm of the study through high-throughput detection of antibodies; assessing the genetic epidemiology (i.e. species, genetic diversity, clonality, drug resistance) of *Plasmodium* parasites in each study arm using molecular and genomic methods; characterizing the social factors affecting the implementation of MCs using interviews; surveying mosquito vectors in and around the houses of subjects enrolled in each arm; evaluating the impact of the interventions using epidemiological compartmental modeling of host-vector interactions; and building research capacity in Odisha and India to help train the next generation of malaria and mosquito vector biologists.

**Study design**

The effectiveness of the MC intervention is being evaluated with a quasi-experimental cluster-assigned stepped-wedge study with a pretest-posttest control group design; clusters (i.e. villages) are not randomized to the intervention. The main aim of the study is to determine if MCs reduce the prevalence of *Plasmodium* infection as detected by PCR. At baseline, villages are assigned to one of three study arms. In year 1, Arm A villages receive MCs for the first time; Arm B villages serve as control villages where no MCs but routine malaria control activities are implemented; and Arm C are villages that have already had at least one round of MCs prior to initiation of this study that continue to receive the MCs, providing an opportunity to study the longer term effects of the MCs. In the second year, both Arm A and Arm B villages receive the intervention (i.e. a non-randomized stepped-wedge design). MC effectiveness is evaluated from epidemiologic surveys and PCR detection of malaria prevalence in villages with MCs as compared to those without MCs.

This proof-of-concept pilot study was designed in part to build and test the relationship with the Odisha Malaria Control Program (MCP) in the Ministry of Health. Because of the relatively short timeline from funding to field implementation, the districts needed to make decisions on where the malaria camps were going to be implemented rather quickly. While randomization was not possible at that time, the MCP did balance the assignment of villages with respect to ecology. The stepped wedge design was chosen for
the same logistical restraints that resulted in the decision to not randomize the villages for this pilot study.

**Description of intervention**

The MCs implemented by the Odisha State MCP in remote forested areas of the state involve teams of health workers visiting villages to educate the population, enhance vector control with LLINs and indoor residual spraying (IRS), and perform village-wide testing with rapid diagnostic tests and treatment for malaria. The MCP has dramatically scaled up efforts to prevent, diagnose, and treat malaria under the DAMaN program, with apparently rapid and impressive results [23]. The first-line treatment for uncomplicated *P. falciparum* as per Indian national guidelines is artesunate 4 mg/kg body weight per day (3 days); sulfadoxine-pyrimethamine (SP) 25 and 1.25 mg/kg body weight, respectively (one dose) on day 1; and primaquine 0.75 mg/kg body weight or 45 mg (one dose) on day two. Similarly, the first-line treatment for *P. vivax* is chloroquine (CQ) 10 mg/kg body weight (day 1 and day 2) and 5 mg/kg body weight (day 3), along with primaquine 0.25 mg/kg body weight (one dose) for 14 days.

The program consists of two and up to three MC rounds administered per annum. The first round (round 1) during the pre-monsoon season includes testing for the whole village population with treatment of RDT+ individuals along with LLIN distribution, IRS, and intensified campaigning with ASHAs. The second round (post-monsoon season, round 2) screens only febrile adults but all children (<5 yr age) and lactating/pregnant mothers regardless of fever status. This is because round 1 is expected to reduce malaria by >90%, and subsequent rounds need only target the remaining febrile cases or potentially asymptomatic cases that have become symptomatic in the interim. The necessity of round 3 MCs is determined based on the coverage and success of rounds 1 and 2 and is, therefore, optional.

For each MC round, the DAMaN team is in each village for one to three days, depending on the size of the village. The MCs also offer a range of malaria awareness activities such as plays containing malaria prevention messages performed by traveling troupes, bednet use ‘performances’ in government high schools with hostels, and vans with loudspeakers that play popular local songs that incorporate malaria prevention guidance in the lyrics and have mosquito control messages displayed on their sides. In addition, the MCs include nutritional screening of children and pregnant women.

**Target population**

The eastern state of Odisha is a predominantly (83%) rural state of approximately 42 million people [4] with ~62% of the rural population consisting of tribal populations, altogether representing >60 different ethnic communities. These tribes inhabit the hilly ranges including in Jharsuguda and Keonjhar districts [24] where the study is located (see Figure 1 for a map of the region). The tribal population makes up to about 30.5% of the total district population in Jharsuguda and 45.5% in Keonjhar [26]. Major tribes in the two districts include Bathudi, Bhuyan, Bhumij, Gond, Ho, Juang, Kharwar, Kisan, Kolha, Kora, Munda, Oraon, Santal, Saora, Shabar and Sounti [27]. The tribal populations in Odisha experience substantial socioeconomic disadvantage, as evidenced by low literacy rates (52.2% overall); underemployment (35% of workers aged 15 years & above worked for 12 months in the last year); few homes with electricity or solar power (15.6 and 0.6%, respectively) as their main lighting source, no latrine on premises (92.9%), or a water source inside (6.2%); and high prevalence of open defecation (92.9%) [28]. Agriculture, mining, quarrying, and household industries are the main types of employment [25].

A recent study in the adjacent Sundargarh district found that behavioral risk factors for malaria include being outside in the evening (34.5% among adult men and 7.9% among adult women aged 15+ years and 0.7% among children) and sleeping outside (7.5% vs. 0.5% and 0%, respectively, p < 0.001). Although women were more likely to get up before 6 a.m. (86.6%, vs. 70.5% among men, 50.7% among children, p < 0.001), men were more likely to be outside in the early morning (77.6% among men, 11.2% among women, and 11.1% among children, p < 0.001). More children used insecticide treated nets the previous night (73.4%) than men (45.6%) or women (39.6%), and repellents were used by 29.5% of 234 households (insecticide creams were not used at all) [29].

Tribal areas such as the Jharsuguda and Keonjhar districts, where this study is situated, are the most seriously afflicted with malaria, displaying meso- to hyperendemic transmission. IRS coverage in malarious regions is approximately 90% and the last ITN distribution was in July/August 2017 [30]. These communities are our target population. Village residents are eligible for the study if they are (1) aged 12 months to 69 years and (2) have an apparent complete understanding of the study procedures as outlined in the consent form. There are no exclusion criteria based on residency length, pregnancy, social class, or health conditions.

**Sample size calculations**

Statistical significance is not the central goal of this two-year pilot study. The sample size was estimated
based on the stated requirement of a minimum of 2,000 participants in the National Institutes of Health request for proposals in concert with study logistics [31]. We used Stata 16.0 to calculate power using the steppedwedge command [32] which is used to calculate power for stepped wedge cluster-randomized controlled trials. We note that this trial is not randomized (i.e. it is cluster-assigned); as a result, power estimation should be interpreted as a guide.

An average village in the malarious areas of Odisha has ~250 (range: 60–850) households and 1,200 (range: 300–4,000) people, and we aim to enroll 163 people per cluster. In our previous studies, *Plasmodium* infection prevalence by PCR in the forest villages around Rourkela was 16% during the rainy season [33], and we consider a difference of 6% (e.g. from 16% to 10%) in *Plasmodium* infection prevalence by PCR after two rounds of MCs between control and intervention clusters measured during the rainy season in the second year, to be a meaningful reduction. For our sample size calculations, we compared between clusters in arm A (intervention) and arm B (control), and used an intracluster correlation coefficient (ICC) of 0.02 (although studies reporting an ICC for a malaria outcome in India could not be found, a study on maternal and neonatal health in India showed that this number may be a conservative estimate compared to outcomes with a similar low prevalence [34]).

We calculated power for the stepped wedge design using Arms A and B; Arm C was not included in the power calculations because we do not have pre-intervention data for that arm. Two study arms of 5 clusters each and an average cluster size of 163 (total sample size 1,630, 1:1 sample size ratio) allows us to detect a reduction from 16.0 to 10.0% prevalence of *Plasmodium* infection by PCR with 80% power and 5% significance level; we use a 15% higher sample size (~187 per cluster, n = 1,870) to allow for loss-to-follow-up.

Revised sample size: Based on our experiences recruiting in the field in August and September 2019, we increased the sample size from 2,244 to 2,700 and add two new clusters (villages). To achieve the sample size of 2,700, we are enrolling one additional village in each arm for a total of six villages each in Arms A and B and three in Arm C (for a total of 15 villages). Six clusters each in Arms A and B and an average cluster size of 163 (total sample size 1,956, 1:1 sample size ratio) allows us to detect a reduction from 16.0 to 10.5% prevalence of *Plasmodium* infection by PCR with 80% power and 5% significance level; we use a 18% higher sample size (~193 per cluster, n = 2,316) to allow for loss-to-follow-up. The increase in sample size allows us to maintain study power, and the rationale for the increase is twofold. First, two of the villages were inhabited by the Juang People, one of the most geographically and culturally isolated tribal
groups specific to the Keonjhar district [35]. Willingness to participate among this group was low, and we anticipate high loss-to-follow up rates from individuals in this tribe despite giving consent. Second, study staff noticed in most villages that some participants discarded their study cards. These study cards are labeled with the study ID number with no personal identifiers and are the way in which we track participants over time. As a result, we are concerned that follow-up rates will be lower than we first anticipated across all villages.

**Sampling of villages and assignment to study arms**

We selected one or more district blocks with a high API (>2) from the study districts. Villages/hamlets are the units of the MCs and are therefore the clusters in this study. We assign the villages/hamlets into two study arms: Arm A ‘new-MC’ (n = 6 villages that start MCs in year 1) and Arm B ‘delayed-MC’ (n = 6 villages with routine malaria control activities in year 1 and MC in year 2). A third study arm (Arm C ‘old-MC’) is comprised of n = 3 villages where MCs have already been implemented, providing an opportunity to assess the effects of the MCs over a longer period of time. After assignment to study arms, a cohort is enrolled during a baseline visit in all the clusters. In the old-MC clusters (where MCs have occurred) and in the clusters not receiving MCs, malaria activities continue as planned by the MCP. In the new-MC clusters, the MC intervention is introduced (one round of screening and treatment for the whole cluster population pre-monsoon, followed by at least one round of screening of adult fever cases, children under 5 years, and pregnant women only post-monsoon). The exact villages and districts were chosen in consultation with the Odisha MCP which balanced the assignments in terms of ecotype (e.g. forest, mining, river, plain, etc.). Because this is a community-based intervention, participants are not blinded.

**Recruitment**

To recruit participants, a field team travels to the villages at the same time when the DAMaN team delivers the intervention. Within each village, the DAMaN team sets up their screening and treatment camps in a central location. Our team sets up their operations adjacent to the DAMaN team. As each village resident completes their DAMaN visit, they are informed of the nature and purpose of the study and invited to enroll.

**Consent**

For those who express interest in the study, field staff read aloud a consent form in one of the local languages (i.e. Oriya or Hindi). Eligible participants are offered a copy of the consent form in the local language to read along with the field staff member. Persons aged 18 years or older who are mentally capable of consenting are provided a consent form to review and sign. For children under seven years of age, a consent form signed by a parent or guardian is required. For children between seven and 17 years of age, parental consent and an additional child assent is required for participation. If a person cannot write, they are asked to place a thumbprint on the consent form in the presence of a literate witness (i.e. another adult in the household or a neighbor), who also signs the form. Ethical approval for the study was obtained from the institutional review board at New York University (New York, NY, USA) and the institutional ethics committee at Community Welfare Society Hospital (Rourkela, Odisha, India). The study was also approved by the Indian Council of Medical Research Health Ministry’s Screening Committee.

**Data collection**

**Survey**

A brief survey is administered to consenting adults and older children (aged 17 and older) via Samsung Galaxy tablets (10.1” 32GB SM-T580 – International Version) loaded with a REDCap (Vanderbilt University, Nashville, TN, USA) mobile application instrument. A parent or guardian provides proxy responses for children aged under 17 years. The survey includes measures of demographics, socioeconomic status (SES), malaria knowledge, malaria prevention, and previous malaria and treatment. With respect to demographics, participants are asked to provide their age, sex, and number of people living in the household; proxy interviewees for children are asked to describe their relationship to the child. SES measures include educational attainment and occupation.

Malaria knowledge focuses on signs and symptoms; respondents are asked open-ended questions and field staff record responses. For malaria prevention, participants are asked if they slept outside and whether they slept under a bednet when they did so. For previous malaria and treatment, participants are asked if they have ever had malaria, when was the last time they had it, whether they sought advice or treatment last time, the time to treatment, whether they were tested for malaria last time, and the result of the last malaria test.

At the time of enrollment, each study participant receives a blue study card with their study participant
number. The study card is a means to provide anthropometric and blood testing results to the study participant at each visit and also allows for participant tracking in subsequent visits.

**Anthropometrics**

Field staff measure each participant’s body temperature, height, weight, and mid upper arm circumference (MUAC). Body temperature is measured temporally in degrees Fahrenheit with a non-contact infrared thermometer (Dr. Morepen FS-300, Korea) to the nearest tenth of a degree. Height is measured with a height measuring tape (PMG Eco Series, India) in centimeters. Weight is measured in kilograms with a scale (Dr. Morepen DS-03, India). MUAC is the circumference of the left upper arm, measured at the mid-point between the tip of the shoulder and the tip of the elbow (i.e. olecranon process and the acromion). Participants are asked to remove any clothes that may hinder the measurement (preferable directly on skin, but tight clothes can be accepted if they are difficult to remove). MUAC is measured in centimeters to one decimal using a Myotape/tape measure (Jyoti IND/09/12/309, India).

**Malaria cost survey**

Participants who self-report having malaria in the past eight weeks are administered a malaria cost survey to assess the total out-of-pocket cost of a malaria illness episode in our study setting alongside the trial. The malaria cost survey has questions eliciting information on treatment-seeking behavior and associated out-of-pocket spending, work and school absenteeism, and income loss incurred by participants or their caregivers during the illness episode.

Out-of-pocket costs include direct and indirect costs borne by households during a malaria illness episode. Direct costs include all out-of-pocket medical (consultation fees, tests, medications) and non-medical (transport, meals, lodging) expenditures for seeking and receiving treatment for malaria while indirect costs consist of lost paid work for participants, or, where applicable, their caregivers during malaria illness. We will value lost paid work due to malaria illness as the higher of the self-reported or estimated income loss; the latter is estimated conservatively as the product of the number of reported work-days lost by the patient or their caregivers and the minimum daily wage for Odisha state set by India’s Labour Bureau [36]. We will also report on the number of school days missed due to malaria illness. The economic value of school absences due to malaria illness is estimated as the product of the number of school-days missed due to illness and the daily per-capita cost of providing education in India [37].

The total out-of-pocket cost per malaria episode is obtained by summing direct and indirect costs. If there are missing cost data, depending on the amount and the reasons for the data being missing, we will apply naive or multiple imputation methods to the dataset to derive unbiased and efficient estimates [38]. We will report the mean, standard deviation, median, and interquartile ranges for costs and days of missed school and work lost per malaria episode. Costs will be reported in US dollars (USD) for the initial year of the trial. All costs are collected in local currency, and will be adjusted for inflation [39], if necessary, before conversion to USD [40].

**Sample collection and processing**

In addition to completion of a study questionnaire and anthropometric measurements, study enrollment procedures include a finger prick by sterile lancet for small blood volume sampling (300 ul; Sarstedt microvette CB300 with EDTA), thin and thick blood smears, blood spots (Whatman FTA Blood Stain Cards), and point of care (POC) testing (e.g. hemoglobin [HemoCue America, Brea, CA], malaria rapid diagnostic test [RDT, described below]). All individuals are screened for *Plasmodium* infection by RDT and species-specific PCR. Vacutainers (5 ml, BD ACD) of venous blood are requested from individuals found to be *Plasmodium* positive by RDT. All vacutainers and small volume microvrettes are immediately refrigerated on ice and shipped overnight in insulated coolers to the main laboratory where they are processed. Blood components (e.g. red blood cells (RBC) pellet, plasma) are isolated and stored at −80°C until assayed.

**Rapid diagnostic testing for *P. falciparum* and *P. vivax**

Finger prick blood samples from all study subjects are tested for *P. falciparum* and *P. vivax* using the point-of-care (POC) test FalciVax (Zephyr Biomedicals, Verna, Goa, India). FalciVax is a lateral flow RDT that detects species-specific *Plasmodium* antigens in the peripheral blood. Using the sample loop included in each RDT kit, five microliters of blood and two drops of buffer are added to the cartridge. The results for each RDT is read after 20 minutes at room temperature and recorded.

**Evaluation of Giemsa-stained blood smears**

Thin smears are fixed in methanol and dried prior to Giemsa staining alongside thick smears. Stained smears are evaluated quantitatively and qualitatively for asexual (i.e. ring, trophozoite, schizont) and sexual (i.e. gametocytes) stage parasites at the species level by two independent microscopists as previously described [33].
Molecular detection of *P. falciparum* and *P. vivax* infection by PCR

The RBC pellet isolated from the small blood volume obtained from each study participant is stored at −80°C until assayed. Upon thawing, DNA is extracted using QIAGEN’s QIAamp DNA mini Kit. A final elution volume of 50 μl is used. Molecular detection of *P. falciparum* and/or *P. vivax* is determined by PCR amplification of multiplex target loci (Pvr47 present as 14 copies in the *P. vivax* genome, and Pfr364 present as 41 copies in the *P. falciparum* genome) as described [41], GoTaq Green Mastermix (Promega), and a Veriti 96-well Fast Thermal Cycler (Applied Biosytems). PCR products are visualized by gel electrophoresis using ethidium bromide and a Gel Doc EZ documentation system (BioRad). Positive and negative controls are included in all experiments, and 10% of samples are assayed at an independent lab for QC purposes.

Plasmodium antibody quantification by Luminex MAGPIX

Seventeen recombinant *P. falciparum* and *P. vivax* proteins and/or peptides (Table 1) are used in the multiplexed, bead-based assay. All antigens are coupled to unique Luminex Magplex magnetic microspheres and stored in the dark at 4°C until use. Plasma pellets isolated from the small blood volume obtained from each study subject are prepared at 1/200 in a buffer of PBS, 0.05% Tween, 0.5% BSA, 0.02% sodium azide, 0.1% casein, 0.5% PVA, 0.5% PVP, and *E. coli* extract. All samples, including controls and blanks, are run in duplicate according to standardized procedures [42]. Plates are analyzed on a Luminex multiplex MAGPIX instrument, and xPONENT software is used for data acquisition (Luminex Corp., Austin, TX). Raw values are determined for all antigens in all samples (raw median fluorescent intensity [MFIAg]) and converted to Net MFI (Net MFIAg = raw MFIAg - background MFIAg) where background MFIAg is the mean MFI of a given antigen in the blank wells. For each antigen, seropositivity is defined as mean Net MFI negative pool plus three standard deviations (SD).

Genetic epidemiology of *Plasmodium* parasites

The *Plasmodium* species composition and complexity of infection for each arm are determined. We use deep sequencing methods [19] to run multiplex amplicon-seq assays that assay (1) *P. falciparum* drug resistance alleles to infer the resistance of circulating parasites to antimalarial drugs, and (2) *P. falciparum* and *P. vivax* highly polymorphic loci for genetic diversity measurements. The latter assay

| Classification | Antigen | Location | Protein function | Antibody function | Source and reference |
|----------------|---------|----------|------------------|-------------------|---------------------|
| *P. falciparum* | EBA140 RIII-V | Micronemes | Erythrocyte invasion | Variable marker of exposure (mid time predictor) | J. Beeson [66] |
|                | EBA175 RIII-V | Micronemes | Erythrocyte invasion | Variable marker of exposure (mid time predictor) | J. Beeson [66] |
|                | EBA180 RIII-V | Micronemes | Erythrocyte invasion | Variable marker of exposure (mid time predictor) | J. Beeson [66] |
|                | Etramp 5.Ag1 | Parasitophorous membrane | Infected erythrocyte surface | Short-term marker of exposure | K. Tetteh [67] |
|                | HSP40.Ag1 | Micronemes | Protein refolding | Short-term marker of exposure | K. Tetteh [68] |
|                | MSP2_Ch150/9 | Micronemes | Erythrocyte invasion | Markers of exposure | Cavanagh [69] |
|                | MSP2_Dd2 | Micronemes | Erythrocyte invasion | Markers of exposure | Cavanagh [69] |
|                | AMA1 | Micronemes | Erythrocyte invasion | Long-term marker of exposure | Blackman/Crick [70] |
|                | GLURP.R2 | Micronemes | Erythrocyte invasion | Long-term marker of exposure | Theisen [71] |
|                | MSP119 | Micronemes | Erythrocyte invasion | Long-term marker of exposure | Holder/NIMR/Crick [72] |
|                | Rh2_2030 | Micronemes | Erythrocyte invasion | Variable marker of exposure (mid time predictor) | J. Beeson [73] |
|                | Rh4_2 | Micronemes | Erythrocyte invasion | Variable marker of exposure (mid time predictor) | J. Beeson [74] |
|                | Rh5.1 | Micronemes | Erythrocyte invasion | Variable marker of exposure (mid time predictor) | Draper/Jenner [75] |
| *P. vivax*     | AMA1 | Micronemes | Erythrocyte invasion | Long-term marker of exposure | C.H. Kocken [76] |
|                | MSP119 | Micronemes | Erythrocyte invasion | Long-term marker of exposure | T. Holder [77] |
|                | MSP8 | Micronemes | Non-essential | Unknown | K. Tetteh; unpublished |
|                | MSP10 | Micronemes | Unknown | Unknown | GE Healthcare NIBSC |

**Controls**

| GST | Tetanus toxoid (TT) | Affinity tag/background control | Internal assay control |

---
determines if, as transmission decreases, there is a decrease in parasite genetic diversity, as has been shown to occur with *P. falciparum* [43]. We also undertake whole genome sequencing of a limited number of single genotype *P. falciparum* and *P. vivax* isolates to determine their genetic diversity and phylogenetics in comparison to our previously sequenced Indian isolates [44,45].

**Follow-up**

Follow-up visits are conducted immediately prior to the MC camps in each intervention village and during roughly the same time period in the comparison villages. Participant IDs are confirmed via presentation of the individual’s blue study card. Follow-up visit procedures parallel those employed during the baseline enrollment visit, including completion of the study questionnaire, anthropometric measurements, malaria RDT and hemoglobin POC testing, and collection of a small volume of blood by finger prick. Vacutainers (5 ml, BD ACD) of venous blood are requested from individuals found to be *Plasmodium* positive by RDT.

**Vector survey**

In each study village, eight randomly selected households and eight cattle sheds are surveyed for mosquitoes using light trap, hand catch, and pyrethrum space spray collection methods. UV light traps are set for a 12 hour window (6 pm to 6 am) both inside and outside of the selected households. Mosquitoes caught in the traps are identified morphologically to the species level, and mosquito density per trap per night is calculated. Hand catch collections of resting mosquitoes are performed inside each household and cattle shed for 15 minutes via sucking tubes. Hand caught mosquitoes are also identified morphologically to the species level, and per hour species mosquito density is calculated. Pyrethrum spray collection of the resting mosquitoes in one bedroom of each village is performed. The collected mosquitoes are identified morphologically to the species level, and per room density is calculated. Blood meals of the vectors are collected on filter paper to identify their feeding behavior. All mosquito collection data are tabulated manually. The selected households are evaluated using a questionnaire to document features and characteristics of the dwelling and surrounding region relevant for parasite transmission and increased risk of infection. The household data are collected via the REDCap Mobile App on Samsung Galaxy tablets.

**Definition of outcomes**

Primary outcome measures are *Plasmodium* presence and species. Parasite presence is defined as PCR-positive for any malaria parasite species, and parasite species are defined as PCR-positive for *P. falciparum* and/or *P. vivax*.

Secondary malaria outcome measures include malaria as detected by RDT, gametocyte density, *Plasmodium*-specific serology, and *Plasmodium* parasite genetic epidemiology. Malaria by RDT is defined as RDT-negative vs. RDT-positive. We further identify asymptomatic and subpatent infections. Asymptomatic infections are defined as PCR and/or RDT positive for any malaria species with absence of documented fever or self-reported fever in the last 48 hours. Subpatent malaria is defined as RDT-negative and PCR-positive. Gametocyte density is measured by quantifying the number of gametocyte infected erythrocytes and dividing by the number of leukocytes. To account for a mixed-infection (either by species or by multiple strains), we take the gametocyte to trophozoite ratio to reduce any apparent bias. *Plasmodium*-specific serology is analyzed as a continuous antibody titer variable as well as a categorical (seropositive vs. seronegative) variable. In terms of *Plasmodium* parasite genomic epidemiology, variables include clonality, genetic diversity, and molecular force of infection.

Secondary anthropometric outcome measures include hemoglobin, body mass index (BMI), body temperature, and MUAC. Hemoglobin is measured by POC testing which provides both continuous and categorical data (when analyzed by local standards) regarding anemia status. BMI is calculated as kilograms/meters$^2$ and analyzed as a continuous and categorical variable. BMI categories (i.e. underweight, normal weight, overweight, and obese) are based on adult and child standards for Asian Indians [46–49]. Body temperature is analyzed as a continuous and categorical variable. We have created two categorical variables for temperature, fever ($\geq 99.5\, ^\circ F$) and hypothermic ($\leq 95.0\, ^\circ F$). MUAC is measured as a continuous and categorical variable indicating malnutrition and based on WHO standards.

**Statistical analyses**

*Plasmodium* infection prevalence by PCR at the third follow-up visit is the main outcome and will be compared across Arms A and B, taking clustering into account with generalized estimating equations in Stata version 16.1 or higher (StatCorp LLC, College Station, TX, USA). The unit of analysis is the individual. Potential confounders will be examined including age, gender, antimalarial use, type of housing, and indicators of socio-economic status at the individual level; malaria intervention use at the household and individual levels, and elevation, village size, and mosquito-habitats (i.e. forest cover, bodies of water) at the village level. We will conduct intent-to-treat analyses. If it is decided that an interim analysis needs to
be conducted, the study design will be adjusted for the p-value spent.

**Modeling**

Mathematical modeling and simulation analyses have the potential to assist with analysis and interpretation of randomized trials of interventions, particularly if trial results are unexpected [50], as well as estimation of the effectiveness of interventions in dynamic conditions beyond the trial period. There is a long history of mathematical models of malaria transmission, ranging from deterministic to stochastic models, with different levels of complexity [51]. We will develop an epidemiological compartmental model with host-vector interactions to study the impact of a combination of interventions (i.e. ITNs, IRS, and MCs) on transmission dynamics of malaria. The model will build on existing compartmental models of malaria employing the widely used Susceptible-Infected-Recovered (SIR) framework to track host and vector populations and their interactions through contact [52,53]; but, we will extend these models to allow for greater host heterogeneity, where hosts can be grouped according to their level of immunity (i.e. non-immune, semi-immune, immune), availability to mosquitoes (i.e. protected and unprotected), and level of infectiousness to mosquitoes based on level of intervention coverage (i.e. vector control and mass screening and treatment). The extended model will be able to accommodate the effects of several types of interventions and provide a platform to (1) assess the impact of interventions singly or in combination, (2) study the consequences of uneven intervention coverage, and (3) determine the most effective combination of interventions in reducing infection rates toward the goal of malaria elimination in the local setting. For this, parameter values to calibrate the model are either obtained directly from the epidemiological or laboratory data collected from the trial, or are estimated statistically using existing datasets from CSCMi for the study setting or from the published literature [54–60]. The model is coupled with a health economic decision model to assess the economic efficiency and sustainability of the intervention strategies that are found to be effective to inform practice and policy, when supporting data on costs of interventions and malaria illness are available. Modelling will be conducted in STELLA Architect system dynamics modeling tool, version 1.9.4. (isee systems, Lebanon, NH, USA)

**Discussion**

By definition of the intervention program criterion, the villages selected by the Odisha state MCP for MCs are located in remote and ‘hard to reach’ parts of the state. Most of the selected villages lack telephone and internet networks and cannot be visited via standard automobile, requiring the study teams to travel long distances on foot. The posed challenges are exacerbated in the months of peak malaria transmission (e.g. monsoon seasons) when rains are frequent and heavy and many of the roadways are inaccessible or washed out entirely. Close coordination of study visits and continued collaboration with the DAMaN teams, the local health centers and personnel including the village ASHAs, and the Odisha state MCP have so far aided greatly in tackling these logistic challenges.

These remote and rural regions of Odisha are largely populated by tribal groups. Some of the study villages in the Keonjhar district are home to the Juang and Munda tribes, two populations that operate largely independent of surrounding communities and are not accustomed to outside contact. Villagers of the stated tribes demonstrated a greater reluctance to participate in the study than observed in other study villages, and many of the individuals who gave initial written consent to participate were not willing to give a blood sample.

**Study status**

On 25 March 2020, the study was temporarily suspended following Prime Minister Narendra Modi’s national lockdown in response to the COVID-19 global pandemic. The national lockdown was imposed in all Indian states with regulations including the closure of all non-essential services and businesses including places of worship, suspension of all education and research operations, suspension of non-essential transportation, prohibition of all social, political, sports and entertainment, and cultural activities, and bans on leaving one’s household. The nationwide lockdown was first extended through 3 May 2020 and subsequently until 8 June 2020. All districts were classified into risk zones (e.g. ‘green’ = 0 reported cases in previous 3 weeks; ‘orange’ = limited number of reported cases; ‘red’ = hotspots) and re-evaluated on a weekly basis. The lockdown was extended through May 31 for all ‘orange’ and ‘red’ zones. The study site districts were ‘orange zones’ at the time of the extension, so study operations remained suspended. The study region began reopening on 8 June 2020, and data collection for the study resumed with the second follow-up visit during the week of 22 June 2020 (Figure 2). Due to the pandemic, we were only able to collect data from five villages for the first follow-up visit.

During the writing of this manuscript, the study protocol of a complementary project ‘DAMaN Assessment’ was published by colleagues at the
Indian Council of Medical Research/Regional Medical Research Centre, Bhubaneswar, India [61].

**Other limitations**

There are several important limitations to this study. Villages were not randomized to study arms, which may result in potential selection bias. However, our assignment of villages aimed to ensure that the distribution of villages across the arms was comparable in terms of ecology and terrain type, presence/absence of mining activity, population size, and API. Given the current COVID-19 pandemic, loss-to-follow-up could lead to selection bias as well. With respect to information bias, all self-reported survey measures, including malaria symptoms and diagnoses, may be subject to recall bias. We note that all participants are surveyed prior to receiving the MC screen and treat protocol, but other activities may be occurring including the educational components of the MC intervention package. This could result in possible information bias, resulting in an overestimation of malaria symptoms knowledge in the study sample.
Summary

Implementation research is intended to combine research approaches and real-life practices to expedite both the general development and delivery of effective public health policies and programs [62]. Here, we apply molecular detection methods, serology, genomics, entomology, costing, and modeling techniques to supplement the ongoing work of the Odisha state MCP with the shared goal of determining the impact of MCs on malaria prevalence, vector populations, and community transmission rates. The MCs represent a major government funded program aimed at combatting a vector-borne disease that poses great health and economic burden to the state. Improved knowledge of MC effectiveness and costing has the potential to improve the program’s delivery, thereby improving both community health and the local economy. The combination of advanced technologies with local expertise and social capital as described here is imperative to tackling global public health problems such as malaria. Our results will be synthesized into a set of recommendations on optimal malaria control strategies and will be presented to the Odisha state MCP.

Acknowledgements

We thank Dr. James Beeson (Burnet Institute, Australia) and Dr. Simon Draper (University of Oxford, UK) for contributing antigens for the serology panel.

Author contributions

AVE, AK, and JC conceptualized the study with input from PS, MMP, and SM. DCO, AK, YT, SS, and JC developed the study design and all methodology with input from all authors. TP, MAH, and PS led the field investigation with DO, AK, YT, SS, and JC providing oversight and project coordination. DO and SS manage the study data. JC acquired the funding. DO, AK, YT, and JC wrote the manuscript with editorial and review contributions from all authors.

Disclosure statement

Madan M. Pradhan is employed by the Odisha State Vector Borne Disease Control Programme, which is the organization that is implementing the intervention. He has a potentially self-serving stake in the research results via potential promotion or career advancement based on outcomes. The other authors have no competing interests to declare.

Ethics and consent

Ethical approval for the study was obtained from the internal review board at New York University (New York, NY, USA) and the institutional ethics committee at Community Welfare Society Hospital (Rourkela, Odisha, India). The study was also approved by the Indian Council of Medical Research Health Ministry’s Screening Committee.

Funding information

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U19AI089676. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Paper context

To address the persistently high rates of malaria in remote and rural regions, the Odisha State (India) Malaria Control Program introduced ‘malaria camps’ to provide education, enhance vector control methods, and perform village-wide screening and treatment. This study protocol describes a cluster-assigned quasi-experimental stepped-wedge study with a pretest-posttest control group design that evaluates if malaria camps reduce the prevalence of malaria, compared to control villages which receive the usual malaria control interventions.

ORCID

Danielle C. Ompad http://orcid.org/0000-0003-0240-0393
Steven A. Sullivan http://orcid.org/0000-0001-9810-0058
Yesim Tozan http://orcid.org/0000-0001-8997-8897
Madan M. Pradhan http://orcid.org/0000-0002-7560-9115
Praveen K. Sahu http://orcid.org/0000-0001-7855-7501
Jane M. Carlton http://orcid.org/0000-0001-9340-5020

References

[1] Global Malaria Programme, WHO Global. World malaria report 2019. Geneva: World Health Organization; 2019. Available from: https://apps.who.int/iris/rest/bitstreams/1262394/retrieve
[2] National Vector Borne Disease Control Program, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Malaria situation in India from 2016. Delhi: Directorate of National Vector Borne Disease Control Programme; 2016. Available from: https://nvbdcp.gov.in/index1.php?lang=1&level=1&sublinkid=5784&id=3689
[3] Government of India. Geography of Odisha. 2012. [cited 2012 Dec 9; 2020 Jun 21]. Available from: https://archive.india.gov.in/knowindia/state_uts.php?id=81.
[4] Office of the Registrar General & Census Commissioner, Ministry of Home Affairs, Government of India. Primary census abstract total 2011. Available from: https://censusindia.gov.in/DigitalLibrary/Tables.aspx
[5] Karlsson BG. Anthropology and the “indigenous slot”: claims to and debates about indigenous peoples’ status in India. In: Karlsson BG, Subba TB, editors. Indigenity in India. London: Kegan Paul; 2006. p. 51–73.
[6] National Commission for Scheduled Tribes, Government of India. National commission for scheduled tribes New Delhi 2019 [cited 2019 Jan 16]. Available from: http://ncst.nic.in/index.asp?langid=1
[7] Sharma RK, Thakor HG, Saha KB, et al. Malaria situation in India with special reference to tribal
areas. Indian J Med Res 2015/ 07/04. PubMed PMID: 26139770; PubMed Central PMCID: PMCPMC4510751. 2015;141:537–545.

Sundararajan R, Kalkonde Y, Gokhale C, et al. Barriers to malaria control among marginalized tribal communities: a qualitative study. PLoS One 2014/ 01/01. PubMed PMID: 24376507; PubMed Central PMCID: PMCPMC3869659. 2013;8:e81966…

Government of India. Districts of India: Odisha 2012 [updated 2012 Dec 21]. Available from: https://archive.india.gov.in/knowindia/districts/andhra1.php? stateid=OR

Panchayati Raj. Drinking Water Department of Government of Odisha. Demographic Details 2018 [21 June 2020]. Available from: https://odishapanchayat.gov.in/english/demographic.asp.

National Health Mission, Department of Health & Family Welfare, Government of Odisha. ASHA 2020 [cited 2020 Jun 21]. Available from: http://www.nrhmorissa.gov.in/frmasha.aspx#:~:text=More%20than%204500%20ASHAs%20in,interventions%20under%20National%20Health%20Mission

Pradhan MM, Meherda PK. Malaria elimination drive in Odisha: hope for halting the transmission. J Vector Borne Dis 2019/ 05/10. PubMed PMID: 31070166. 2019;56:53–55.

Nanda N, Yadav RS, Subbarao SK, et al. Studies on Anopheles fluviatilis and Anopheles culicifacies sibling species in relation to malaria in forested hilly and deforested riverine ecosystems in northern Odissa, India. J Am Mosq Control Assoc. 2000;16:199–205. PubMed PMID: 11081646.

Sahu SS, Gunasekaran K, Krishnamoorthy N, et al. Bionomics of Anopheles fluviatilis and Anopheles culicifacies (Diptera: Culicidae) in relation to malaria transmission in East-Central India. J Med Entomol. 2017;54:821–830. PubMed PMID: WOS:000405349000003.

Das M, Das B, Patra AP, et al. Anopheles culicifacies sibling species in Odisha, eastern India: first appearance of Anopheles culicifacies E and its vectorial role in malaria transmission. Trop Med Int Health. 2013;18:810–821. PubMed PMID: 23621708.

Sharma SK, Tyagi PK, Padhan K, et al. Epidemiology of malaria transmission in forest and plain ecotype villages in Sundargarh District, Orissa, India. Trans R Soc Trop Med Hyg. 2006;110:917–925. PubMed PMID: 16697022.

Smith DL, Perkins TA, Reiner RC Jr., et al. Recasting the theory of mosquito-borne pathogen transmission dynamics and control. Trans R Soc Trop Med Hyg. 2014;108:185–197. PubMed PMID: 24591453; PubMed Central PMCID: PMCPMC3952634.

Antony HA, Das S, Parija SC, et al. Sequence analysis of pfcr and pfmdr1 genes and its association with chloroquine resistance in Southeast Indian Plasmodium falciparum isolates. Genom Data Epub 2016/ 05/26. PubMed PMID: 27222806; PubMed Central PMCID: PMCPMC4856815. 2016;8:85–90.

Rao PN, Uplekar S, Kalyal S, et al. A method for amplicon deep sequencing of drug resistance genes in Plasmodium falciparum clinical isolates from India. J Clin Microbiol. 2016;54:1500–1511. PubMed PMID: 27008882; PubMed Central PMCID: PMCPMC4879288.

Kar NP, Chauhan K, Nanda N, et al. Comparative assessment on the prevalence of mutations in the Plasmodium falciparum drug-resistant genes in two different ecotypes of Odisha state. India. Infect Genet Evol. 2016;41:47–55. PubMed PMID: 26988711; PubMed Central PMCID: PMCPMC4868809.

Mallick PK, Joshi H, Vanceha N, et al. Mutant pfcr “SVMNT” haplotype and wild type pfmdr1 ”N86” are endemic in Plasmodium vivax dominated areas of India under high chloroquine exposure. Malar J. 2012;11:16. Epub 2012/ 01/13. PubMed PMID: 22236376; PubMed Central PMCID: PMCPMC3283508.

Rana R, Ranjit M, Bal M, et al. Sequence analysis of the K13-propeller gene in artemisinin challenging Plasmodium falciparum isolates from malaria endemic areas of Odisha, India: a molecular surveillance study. Biomed Res Int. 2020/ 04/08. PubMed PMID: 32258150; PubMed Central PMCID: PMCPMC7102476 publication of this manuscript.

World Health Organization. India takes on malaria in its highest burden state 2018 [cited 2018 Jun 22; 2020 Mar 22; 2018 Jun 14; 2018 Mar 22]. Available from: http://www.who.int/malaria/news/2018/india-takes-on-malaria/en/

Bisai S, Saha KB, Sharma RK, et al. An overview of tribal population in India: introduction. 2014. Available from: https://www.nirth.res.in/publications/tribal_health_bulletin/tbh_special_issue2014.pdf

Census of India, Odisha Directorate of Census Operations. Census of India 2011, Odisha: District Census Handbook Kendujhar. 2011. Available from: https://cdn.s3waas.gov.in/s307cdfd23373b17c6bb337251c22b7ea57/uploads/2018/05/2018051755.pdf

Census of India, Odisha Directorate of Census Operations. Census of India 2011, Odisha. District Census Handbook Jharsuguda 2011. Available from: https://censusindia.gov.in/2011census/dchb/2102_PART_B_DCHB_JHARSUGUDA.pdf.

Government of India, Ministry of Home Affairs, CommissionerOffice of the Registrar General & Census Commissioner. Keonjhar district population data, 2011 Census 2011 [cited 2020 Jul 29]. Available from: https://cdn.s3waas.gov.in/s307cdfd23373b17c6bb337251c22b7ea57/uploads/2018/05/2018052344.pdf.

Government of India, Ministry of Tribal Affairs. Annual report 2019–20. New Delhi: Ministry of Tribal Affairs, 2020. Available from: https://tribal.nic.in/downloads/annual-report/AREnglish1920.pdf

van Eijk AM, Choubey S, Barla P, Haque MA, Nandini P, Acharya S, et al. Malaria in SundargarhDistrict, Odisha, India: Epidemiological and behavioral aspects from surveys. Acta Trop. 2020;211:105647. Epub 2020/08/01. doi:10.1016/j.actatropica.2020.105647. PubMed PMID: 32735794; PubMed Central PMCID: PMCPMC7494530

Government of India, Ministry of Health & Family Welfare, Directorate General of Health Services, Directorate of National Vector Borne Disease Control Programme. Strategic Plan for Malaria Control in India 2012-2017: A Five-year Strategic Plan. 2012. 2012 Contract No.: 29 July 2020. Available from: http://nvbdcp.gov.in/Doc/Strategic-Action-Plan-Malaria-2012-17-Co.pdf.

National Institutes of Health, National Institute of Allergy and Infectious Diseases. RFA-A1-17-044: limited competition: revision applications for international centers of excellence for malaria research (U19 clinical trial optional). In: Department of Health Human Services, editor. Bethesda, MD; 2017.
[32] Hemmeng K, Girling A. A menu-driven facility for power and detectable-difference calculations in stepped-wedge cluster-randomized trials. Stata J. 2014;14:363–380.

[33] Van Eijk AM, Sutton PL, Ramanathapuram L, et al. The burden of submicroscopic and asymptomatic malaria in India revealed from epidemiology studies at three varied transmission sites in India. Sci Rep. 2019;9:17095. Epub 2019/11/21. PubMed PMID: 31745160; PubMed Central PMCID: PMCPMC6863831.

[34] Pagel C, Prost A, Lewycka S, et al. Intracluster correlation coefficients and coefficients of variation for perinatal outcomes from five cluster-randomised controlled trials in low and middle-income countries: results and methodological implications. Trials. 2011;12:151. PubMed PMID: 21672223; PubMed Central PMCID: PMCPMC3136407.

[35] Sahoo LK. Socio-economic profile of tribal populations in Mayurbhanj and Keonjhar districts. Orissa Rev. 2011;1:63–68.

[36] Labour Bureau, Ministry of Labour, Government of India. Wage rates in Rural India 2020. Available from: http://labourbureau.gov.in/

[37] Bose S, Ghosh P, Sardana A Resource requirements for Right to Education (RTE): normative and the real. eSocialSciences [Internet]. 2017; Working Papers id:12137.

[38] Briggs A, Clark T, Wolstenholme J, et al. Missing... presumed at random: cost-analysis of incomplete data. Health Econ. Epub 2003/04/30. PubMed PMID: 12720255. 2003;12:377–392.

[39] World Bank. Inflation, GDP deflator (annual %). Washington, DC: World Bank; 2018. Available from: https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG

[40] World Bank. Official exchange rate (LCU per US$, period average) Washington, DC: World Bank; 2018. Available from: https://data.worldbank.org/indicator/PA.NUS.FCRF

[41] Demas A, Obersteller J, DeBarry J, et al. Applied genomics: data mining reveals species-specific malaria diagnostic targets more sensitive than 18S rRNA. J Clin Microbiol. 2011;49:2411–2418. Epub 2011/04/29. PubMed PMID: 21525225; PubMed Central PMCID: PMCPMC3147814.

[42] Wu L, Hall T, Ssewanyana I, et al. Optimisation and standardisation of a multiplex immunosassay of diverse Plasmodium falciparum antigens to assess changes in malaria transmission using sero-epidemiology. Welcome Open Res. 2019;4:26. Epub 2020/06/13. PubMed PMID: 32518839; PubMed Central PMCID: PMCPMC7255915.

[43] Anderson TJ, Haubold B, Williams JT, et al. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol. 2000;17:1467–1482. Epub 2000/10/06. PubMed PMID: 11018154.

[44] Hupalo DN, Luo Z, Melnikov A, et al. Population genomics studies identify signatures of global dispersal and drug resistance in Plasmodium vivax. Nat Genet. 2016;48:953–958. PubMed PMID: 27348298; PubMed Central PMCID: PMCPMC5347536.

[45] Carlton JM. The Evolutionary Genomics of Plasmodium in India. BioMalPar XVI: Biology and Pathology of the Malaria Parasite - Virtual Conference. 18 - 19 May 2020. Keynote lecture.

[46] World Health Organization, WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization, 2006. Available from: https://www.who.int/childgrowth/standards/Technical_report.pdf?ua=1

[47] Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163–170. Epub 2009/07/09. PubMed PMID: 19582986.

[48] Aziz N, Kallur SD, Nirmalan PK. Implications of the revised consensus body mass indices for Asian Indians on clinical obstetric practice. J Clin Diagn Res Epub 2014/07/06. PubMed PMID: 24995216; PubMed Central PMCID: PMCPMC4080037. 2014;8:OC01–OC03.

[49] Indian Academy of Pediatrics Growth Charts C. Khadilkar V, Yadav S, Agrawal KK, et al. Revised IAP growth charts for height, weight and body mass index for 5- to 18-year-old Indian children. Indian Pediatr. 2015;52:47–55. Epub 2015/02/02. PubMed PMID: 25638185.

[50] Halloran ME, Auranen K, Baird S, et al. Simulations for designing and interpreting intervention trials in infectious diseases. BMC Med. 2017;15:223. Epub 2017/12/31. PubMed PMID: 29287587; PubMed Central PMCID: PMCPMC5747936.

[51] Mandal S, Sarkar RR, Sinha S. Mathematical models of malaria - a review. Malar J Epub 2011/07/23. PubMed PMID: 21777413; PubMed Central PMCID: PMCPMC3162588. 2011;10:202.

[52] Ngwa GA. Modelling the dynamics of endemic malaria in growing populations. Discrete Contin Dyn Syst Ser B. 2004;11:1203–1214.

[53] Ngwa GA, Shu WA. A mathematical model for endemic malaria with variable human and mosquito populations. Math Comput Model. 2000;32:747–763.

[54] Churcher TS, Tafe J-F, Cohuet A. Human-to-mosquito transmission efficiency increases as malaria is controlled. Nat Commun. 2015;6:ARTN 6054. PubMed PMID: WOS:000348830300001.

[55] Shapiro LLM, Whitehead SA, Thomas MB. Quantifying the effects of temperature on mosquito and parasite traits that determine the transmission potential of human malaria. PLOS Biol. 2017;15:ARTN e2003489. PubMed PMID: WOS:000414060400010.

[56] Dawes EI, Churcher TS, Zhuang S, et al. Anopheles mortality is both age- and Plasmodium-density dependent: implications for malaria transmission. Malaria J. 2009;8:ArtN 228. PubMed PMID: WOS:000271601400003.

[57] Churcher TS, Sinden RE, Edwards NJ, et al. Probability of transmission of malaria from mosquito to human is regulated by parasite density in naive and vaccinated hosts. Am J Trop Med Hyg. 2017;97:230. PubMed PMID: WOS:0004232152040107.

[58] Bryt OJT. A simple method for calculating mosquito mortality rates, correcting for seasonal variations in recruitment. Med Vet Entomol. 2002;16:22–27. PubMed PMID: WOS:000174976000003.

[59] Bartoloni A, Zammarchi L. Clinical aspects of uncomplicated and severe malaria. Mediterr J Hematol Infect
[60] Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22:13–36. Table of Contents. Epub 2009/01/13. PubMed PMID: 19136431; PubMed Central PMCID: PMCPMC2620631.

[61] Bal M, Das A, Ghosal J, et al. Assessment of effectiveness of DAmAn: a malaria intervention program initiated by Government of Odisha, India. PLoS One. 2020;15:e0238323. Epub 2020/09/09. PubMed PMID: 32898853.

[62] Theobald S, Brandes N, Gypong M, et al. Implementation research: new imperatives and opportunities in global health. Lancet. 2018;392:2214–2228. Epub 2018/10/14. PubMed PMID: 30314860.

[63] Wu L, Mwesigwa J, Affara M, Bah M, Correa S, Hall T, Singh SK, Beeson JG, Tetteh KKA, Kleinschmidt I, D’Alessandro U, Drakeley C. Cero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration. BMC Med. 2020 Nov 13;18(1):331. PMID: 33183292; PMCID: PMC7664049.

[64] Wu L, Mwesigwa J, Affara M, Bah M, Correa S, Hall T, Singh SK, Beeson JG, Tetteh KKA, Kleinschmidt I, D’Alessandro U, Drakeley C. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia. BMC Med. 2020; Sep 25;18(1):304. PMID: 32972398; PMCID: PMC7517687.

[65] Billingsley PF, Sim BKL, Hoffman SL, Drakeley C, Bousema T, D’Alessandro U. Serologic Markers of Previous Malaria Exposure and Functional Antibodies Inhibiting Parasite Growth Are Associated With Parasite Kinetics Following a Plasmodium falciparum Controlled Human Infection. Clin Infect Dis. 2020 Jun 10;70(12):2544–2552. PMID: 31402382; PMCID: PMC7286377.

[66] Richards JS, Stanisic DJ, Fowkes FJ, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis. 2010;51:e50–e60. Epub 2010/09/17. PubMed PMID: 20843207.

[67] Spielmann T, Fergusen DJ, Beck HP. Ettramps, a new Plasmodium falciparum gene family coding for developmentally regulated and highly charged membrane proteins located at the parasite-host cell interface. Mol Biol Cell Epub 2003/04/11. PubMed PMID: 12686607; PubMed Central PMCID: PMCPMC153120. 2003;14:1529–1544.

[68] Helb DA, Tetteh KK, Felgnar PL, et al. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. Proc Natl Acad Sci USA. 2015;112:E4438–E4447. Epub 2015/07/29. PubMed PMID: 26216993; PubMed Central PMCID: PMCPMC4538641.

[69] Polley SD, Conway DJ, Cavanagh DR, et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine. 2006;24:4233–4246. Epub 2005/08/23. PubMed PMID: 16111789.

[70] Collins CR, Withers-Martinez C, Bentley GA, et al. Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J Biol Chem Epub 2006/12/29. PubMed PMID: 17192270; 2007;282:7431–7441.

[71] Theisen M, Vuust J, Gottschau A, et al. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol Epub 1995/01/01. PubMed PMID: 7719909; PubMed Central PMCID: PMCPMC170096. 1995;2:30–34.

[72] Burghaus PA, Holder AA. Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol Epub 1994/03/01. PubMed PMID: 8078519. 1994;64:165–169.

[73] Triglia T, Thompson J, Caruana SR, et al. Identification of proteins from Plasmodium falciparum that are homologous to reticulocyte binding proteins in Plasmodium vivax. Infect Immun Epub 2001/02/13. PubMed PMID: 11160005; PubMed Central PMCID: PMCPMC97989. 2001;69:1084–1092.

[74] Reiling L, Richards JS, Fowkes FJ, et al. The Plasmodium falciparum erythrocyte invasion ligand Pfcrb4 as a target of functional and protective human antibodies against malaria. PLoS One. 2012;7:e45253. Epub 2012/10/03. PubMed PMID: 23028883; PubMed Central PMCID: PMCPMC3447948.

[75] Crosnier C, Bastamante LY, Bartholdson SL, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature. 2011;480:534–537. Epub 2011/11/15. PubMed PMID: 22080952; PubMed Central PMCID: PMCPMC3245779.

[76] Kocken CH, Dubbeld MA, Van Der Wea, Pronk JT, Waters AP, Langermans JA, Thomas AW. Highlevelexpression of Plasmodium vivax apical membrane antigen1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macacmulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. InfectImmun. 1999 Jan;67(1):43-9. doi: 10.1128/IAI.67.1.43-49.1999.PMID: 9864194; PMCID: PMC69275.

[77] Babon JF, Morgan WD, Kelly G, EcclestonJF, Feeney J, Holder AA. Structural studies on Plasmodiumvivax merozoite surface protein-1. Mol Biochem Parasitol. 2007May;153(1):31-40. doi: 10.1016/j.molbi para.2007.01.015. Epub2007 Jan 30. PMID: 17343930.